Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.

British journal of clinical pharmacology - 1 Sept 2014

Chen Ya-Chi, Bernaards Coen, Kulkarni Rohit, Moreira Sebastian, Zhu Yonghong, Chan Anna, Badman Ethan, Ackrill Andrew, Thommes James, Smith Patrick F

Abstract excerpt

AIMS: The aim was to evaluate early viral kinetics in patients receiving mericitabine [hepatitis C virus (HCV) nucleoside polymerase inhibitor] with peginterferon alfa-2a (40KD) and ribavirin in two clinical trials (PROPEL and JUMP-C). METHODS: We examined rapid virological responses (RVRs; week 4 HCV RNA <15 IU ml(-1) ) and complete early virological responses (cEVR; week 12 HCV RNA <15 IU ml(-1) ) in HCV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase II as Topic
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Share to Randomized Controlled Trials as Topic

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 24602156
DOI: 10.1111/bcp.12369
PMCID: PMC4243904

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.PMID 24602156Read ↗

PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.Semantic proximity Read ↗

JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.Semantic proximity Read ↗

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).Semantic proximity Read ↗

Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.Semantic proximity Read ↗

Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.Semantic proximity Read ↗

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.Semantic proximity Read ↗

Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.Semantic proximity Read ↗

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.Semantic proximity Read ↗

Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Ribavirin improves early responses to peginterferon through improved interferon signaling.Semantic proximity Read ↗

Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of HCV Rna-Dependent RNA PolymeraseSemantic proximity Read ↗

Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.